Working… Menu

Expanded Access to NanoDoce

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04060628
Expanded Access Status : Available
First Posted : August 19, 2019
Last Update Posted : September 9, 2020
US Biotest, Inc.
Information provided by (Responsible Party):
NanOlogy, LLC

Tracking Information
First Submitted Date August 14, 2019
First Posted Date August 19, 2019
Last Update Posted Date September 9, 2020
Descriptive Information
Brief Title Expanded Access to NanoDoce
Official Title Expanded Access to NanoDoce
Brief Summary NanOlogy may consider offering expanded access to NanoDoce for patients who do not meet the enrollment criteria of clinical trials in progress.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Individual Patients
Condition Urogenital Neoplasms
Intervention Drug: NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension
Other Name: docetaxel
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status Available
Eligibility Criteria

Inclusion Criteria:


Exclusion Criteria:


Sex/Gender Not Provided
Ages Child, Adult, Older Adult
Contact: Gere diZerega, MD 805-595-1300
Listed Location Countries Not Provided
Removed Location Countries  
Administrative Information
NCT Number NCT04060628
Other Study ID Numbers NANODOCE-EA
Responsible Party NanOlogy, LLC
Study Sponsor NanOlogy, LLC
Collaborators US Biotest, Inc.
Investigators Not Provided
PRS Account NanOlogy, LLC
Verification Date September 2020